糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗(Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate) - 药物靶点：GR x M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor x β2-adrenergic receptor_在研适应症：哮喘，慢性支气管炎，慢性阻塞性肺疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Closed Triple、Elebrato Ellipta、FF/UMEC/VI

+ [19]

靶点

GR x M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor x β2-adrenergic receptor

作用方式

激动剂、拮抗剂

作用机制

GR激动剂(糖皮质激素受体激动剂)、M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)

治疗领域

免疫系统疾病感染呼吸系统疾病

在研适应症

哮喘慢性支气管炎慢性阻塞性肺疾病+ [1]

非在研适应症

心血管疾病冠状动脉疾病高血压+ [4]

原研机构

GSK Plc

在研机构

GlaxoSmithKline Intellectual Property Development Ltd.GlaxoSmithKline KKGlaxoSmithKline Trading Services Ltd.

+ [3]

非在研机构

权益机构

Theravance Biopharma, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2017-09-18),

慢性阻塞性肺疾病

最高研发阶段(中国)批准上市

特殊审评特殊审批 (中国)

登录后查看时间轴

结构/序列

分子式C44H49Cl2NO7

InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N

CAS号503070-58-4

查看全部结构式(3)

关联

42

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的临床试验

NCT07192016

/ Not yet recruiting临床4期IIT

Mechanistic 129-Xe MRI Study of Single Inhaler FF/UMEC/VI Effects in COPD Patients With Persistent, Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol (VI)-a long-acting β2-adrenergic agonist) works to treat adults with COPD. The investigators will compare the effects of this medication on adults with COPD who are at low risk of a flare-up and adults with COPD who are at high risk of a flare-up. The main questions it aims to answer are:
* Does FF/UMEC/VI improve ventilation defect percent as measured on 129-Xenon MRI in adults with moderate-severe COPD
* Evaluate the relationships between the ventilation defect percent and lung function test results
Participants will:
* Take the inhaler FF/UMEC/VI once daily for 12-weeks (optional 48-weeks)
* visit Robarts 2 times (with optional 3rd visit) for tests and imaging

开始日期2026-03-01

申办/合作机构

University of Western Ontario

NCT06905483

/ Recruiting临床4期IIT

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs.
The main questions it aims to answer are:
* Does BGF demonstrate a comparable effect to FUV in COPD participants?
* What medical problems do participants experience when taking BGFand FUV?

开始日期2025-04-01

申办/合作机构

Thammasat University

NCT06474039

/ Recruiting临床3期IIT

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators

开始日期2024-10-01

申办/合作机构

Mahidol University

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的临床结果

登录后查看更多信息

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的转化医学

登录后查看更多信息

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的专利（医药）

登录后查看更多信息

27

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的文献（医药）

2025-12-01·Pulmonary Therapy

Exacerbation Reduction in Patients with Asthma Following Escalation to FF/UMEC/VI from ICS/LABA: Retrospective Cohort Study

Article

作者: Moore, Alison ; Baptist, Alan P ; Laliberté, François ; Paczkowski, Rosirene ; Schell, Robert C ; Forero-Schwanhaeuser, Sergio ; Germain, Guillaume ; Klimek, Jacob ; Noorduyn, Stephen G

INTRODUCTION:

Despite fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) being available for asthma treatment in the US (United states) since 2020, real-world evidence on its clinical and economic benefits in patients with asthma is lacking. This study aimed to assess the effectiveness of FF/UMEC/VI (100/62.5/25 µg and 200/62.5/25 µg) in US patients with asthma previously on inhaled corticosteroid/long-acting β₂-agonists (ICS/LABA) using administrative claims data.

METHODS:

Retrospective, longitudinal, pre-post study utilizing data from the Komodo Health database between 09/09/2019 and 12/31/2023. Eligible adults with asthma had been treated with ICS/LABA prior to FF/UMEC/VI initiation (index date: first FF/UMEC/VI prescription). Rates of moderate-severe exacerbations, asthma-related healthcare resource utilization, oral corticosteroid (OCS) and short-acting β₂-agonist (SABA) use, and asthma-related medical costs were evaluated pre- (12 months pre-index) and post-FF/UMEC/VI initiation (12 months post-index). Statistical analyses involved rate ratios (RRs) from a Poisson regression model, odds ratios (ORs) from logistic regression models, and mean differences from linear regression models. Exploratory analyses stratified these results by pre-index ICS/LABA combination and FF/UMEC/VI index dose.

RESULTS:

In total, 17,959 patients were included. Following FF/UMEC/VI initiation, odds of having ≥ 1 exacerbation were reduced by 52% (OR [95% confidence interval (CI)] 0.48 [0.46, 0.50]; P < 0.001), rate of moderate-severe exacerbations reduced by 38% (RR [95% CI] 0.62 [0.61, 0.64]; P < 0.001) and asthma-related hospitalizations by 25% (RR [95% CI] 0.75 [0.68, 0.83]; P < 0.001). Odds of ≥ 1 OCS dispensing were reduced by 36% (OR [95% CI] 0.64 [0.62, 0.67]; P < 0.001) and ≥ 1 SABA canister use by 54% (OR [95% CI]: 0.46 [0.44, 0.48]; P < 0.001) post initiation; mean annualized asthma-related medical costs were reduced by $1115 ([95% CI] [$ -1771, $ -459]; P < 0.001). Both FF/UMEC/VI dosage groups had similar results.

CONCLUSIONS:

In patients who remain uncontrolled despite ICS/LABA treatment, escalating to FF/UMEC/VI is associated with reductions in asthma exacerbations, asthma-related hospitalizations, OCS use, SABA use, and asthma-related medical costs.

2025-07-01·Respiratory Investigation

Analysis of adherence to ICS/LAMA/LABA in patients with asthma: a retrospective observational cohort study using medical claims data

Article

作者: Yarita, Masao ; Oga, Toru ; Ito, Risako ; Mukai, Isao ; Requena, Gema ; Mita, Chifuku ; Takano, Masashi

BACKGROUND:

Real-world evidence of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) use in Japan is limited. This real-world study assessed adherence to FF/UMEC/VI once-daily single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) among patients with asthma in Japan.

METHODS:

Retrospective observational cohort study of patients with asthma initiating FF/UMEC/VI SITT or MITT, using claims data (02/18/2021-02/28/2022, JMDC database). Patients were aged ≥15 years at index (date of FF/UMEC/VI or MITT claim). Outcomes were assessed in two cohorts and weighted using inverse probability of treatment weighting: 1) 'overall cohort' included patients who received FF/UMEC/VI or MITT as initial maintenance therapy (IMT) or as non-IMT (i.e., had previously received inhaled corticosteroid-containing medication during baseline); 2) 'non-IMT cohort' was a sub-cohort of the overall cohort.

PRIMARY OUTCOME:

proportion of adherent patients (proportion of days covered ≥0.8) in the 3, 6, and 12 months after, and including, index date.

RESULTS:

The overall cohort comprised 7228 (FF/UMEC/VI) and 864 (MITT) patients. Of these, 3623 and 735 were included in the FF/UMEC/VI and MITT non-IMT cohort, respectively. At 3 months post-index, a significantly higher proportion of patients were adherent to FF/UMEC/VI (36.4 % [n = 2631]) versus MITT (31.2 % [n = 270]) in the overall cohort (rate ratio [95 % confidence interval], 1.16 [1.05-1.29], p = 0.003, weighted), and FF/UMEC/VI (36.6 % [n = 1326]) versus MITT (28.9 % [n = 213]) in the non-IMT cohort (1.26 [1.12-1.43], p < 0.001). Similar results were observed at 6, and 12 months post-index.

CONCLUSIONS:

Patients with asthma in Japan who initiated FF/UMEC/VI SITT had significantly better treatment adherence than those who initiated MITT.

2025-03-01·Pulmonary Therapy

Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA

Article

作者: Laliberté, Francois ; Paczkowski, Rosirene ; Burrows, Emmeline ; Duh, Mei Sheng ; Mahendran, Malena ; Settipane, Russell A ; Germain, Guillaume ; Hilts, Annalise

INTRODUCTION:

Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β₂-agonist; however, characterization of elderly users of triple therapy is limited. This real-world cohort study describes demographics and clinical characteristics of elderly patients with asthma with and without comorbid chronic obstructive pulmonary disease (COPD) who are new users of triple therapy, and asthma treatment patterns preceding triple therapy initiation.

METHODS:

This retrospective cohort study used administrative claims data from the Optum Clinformatics Data Mart database. Eligible patients were ≥ 65 years of age with asthma or with asthma and comorbid COPD who initiated either triple therapy with single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; 100/62.5/25 μg) or MITT between September 18, 2017 and September 30, 2020. Demographics, clinical characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns were described in the 12-month period before triple therapy initiation (baseline period).

RESULTS:

In total, 15,557 patients were included. Among FF/UMEC/VI initiators with asthma (N = 635) mean age was 73.3 years and 66.6% were female. During the baseline period, > 75% of patients used controller therapy, > 92% used rescue medications, 27.9% experienced ≥ 1 asthma-related exacerbation, with mean annual exacerbation rate of 0.42, and mean all-cause healthcare costs were $23,407. Patients with asthma initiating MITT and patients with asthma and comorbid COPD initiating FF/UMEC/VI or MITT had similar characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns to FF/UMEC/VI initiators with asthma.

CONCLUSIONS:

Triple therapy is often initiated following use of other asthma controller medications in real-world practice. Substantial rescue medication use and high disease and economic burden among this elderly patient population suggest that their asthma was not adequately controlled prior to triple therapy initiation. This retrospective study provides an early profile of elderly patients with asthma in the USA.

155

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的新闻（医药）

2026-01-27

·BioSpace

Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA

SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy® Ellipta® 1 100/62.5/25, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Based on the FDA’s public records, 2 Transpire Bio believes that it was the first company to ANDA with a Paragraph IV certification under the provisions of the Hatch-Waxman Act. Should Transpire Bio be the first to ANDA against the RLD, the company may become eligible for 180 days of market exclusivity. In the U.S., Trelegy® Ellipta® is indicated for the maintenance treatment of asthma in patients 18 years and older and the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). According to the GSK Annual Report, Trelegy® Ellipta® recorded U.S. annual net sales of nearly $2.7 Billion 3 in 2024. “The FDA’s acceptance for filing of our ANDA for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy® Ellipta®, is another major milestone in advancing our complex generic franchise,” said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. “Our highly experienced team in South Florida continues to work tirelessly to achieve important milestones like this. We are now one step closer to providing patients suffering from asthma or COPD with an affordable option and improved access to this critical medication.” “This milestone is a result of Transpire Bio’s deep scientific and technical competence, and demonstrates Transpire Bio’s strong capabilities in developing complex drug device combination products,” said Dr. Abhishek Gupta, Chief Scientific Officer of Transpire Bio. In addition to its focused generic franchise, Transpire Bio is building a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), with three assets in development. Transpire Bio is also developing therapies for Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, and neurological diseases. These products are being developed and manufactured in Transpire Bio’s state-of-the-art manufacturing facilities located in South Florida, U.S. Trelegy® Ellipta® is a registered trademark of the GSK group of companies FDA’s list of drug products for which an ANDA has been received by the Office of Generic Drugs containing a “Paragraph IV” patent certification GSK Annual Report 2024 About Transpire Bio Inc. Transpire Bio Inc. is an integrated US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio harnesses its inhaled drug delivery expertise to improve patients’ lives by expanding access to important therapies and developing treatments for serious diseases where therapeutic options are significantly lacking. Transpire Bio has developed multiple proprietary inhalation technology platforms, including dry-powder inhalers and soft-mist inhalers. For more information, please visit . Corporate Inquiries info@transpirebio.com +1 954.908.2233 Investor Inquiries Stuart Loesch Chief Commercial Officer, Transpire Bio Stuart.Loesch@transpirebio.com

2026-01-26

·药菓

一周新药动态|GPC3 RDC BAY3547926，LP(a)抑制剂HRS-5346

向左滑动开始闯关恭喜你闯关成功 ACVR2A-Fc融合蛋白索特西普肺动脉高压 1月23日，默沙东ACVR2A-Fc融合蛋白索特西普拟纳入优先审评，用于治疗成人肺动脉高压 PreS1中和抗体立贝韦塔单抗丁型肝炎病毒感染 1月23日，华辉安健PreS1中和抗体立贝韦塔单抗附条件获批上市，用于治疗伴有或不伴有代偿期肝硬化的慢性丁型肝炎病毒感染 OX2R激动剂奥博雷通 1型发作性睡病 1月23日，武田OX2R激动剂奥博雷通拟纳入优先审评，用于治疗16岁及以上1型发作性睡病 NLRP3抑制剂ISM8969 帕金森 1月23日，英矽智能NLRP3抑制剂ISM8969获FDA临床许可，用于帕金森病治疗 IL-13/IL-31R双特异性抗体ZL-1503 中重度特应性皮炎 1月22日，再鼎医药IL-13/IL-31R双特异性抗体ZL-1503国内获批临床，拟开发治疗中重度特应性皮炎氟替美维吸入粉雾剂哮喘 1月22日，葛兰素史克氟替美维吸入粉雾剂在华获批新适应症，用于哮喘 IL-23抑制剂利生奇珠单抗中重度活动性溃疡性结肠炎 1月22日，艾伯维IL-23抑制剂利生奇珠单抗在华获批新适应症，用于治疗对传统治疗或生物制剂治疗应答不足、失应答或不耐受的中重度活动性溃疡性结肠炎 HER2 ADC德曲妥珠单抗胃或胃食管结合部腺癌 1月22日，第一三共HER2 ADC德曲妥珠单抗国内获批上市，单药用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌 CDH6 ADC Raludotatug deruxtecan 输卵管癌 1月22日，第一三共CDH6 ADC Raludotatug deruxtecan纳入突破性治疗品种，用于治疗既往接受过贝伐珠单抗治疗且CDH6表达的铂耐药上皮性卵巢癌、原发性腹膜癌或输卵管癌 PD-L1抗体度伐利尤单抗子宫内膜癌 1月22日，阿斯利康PD-L1抗体度伐利尤单抗在华获批新适应症，与卡铂和紫杉醇联合用于错配修复缺陷的原发晚期或复发性子宫内膜癌的一线治疗，随后单药维持治疗 CD7 CAR-T细胞疗法WU-CART-007 淋巴细胞白血病 1月21日， Wugen抗CD7 CAR-T细胞疗法WU-CART-007获FDA突破性疗法认定，用于复发或难治性T细胞急性淋巴细胞白血病或T细胞母细胞性淋巴瘤 GIP/GLP-1双受体激动剂替尔泊肽代谢相关脂肪性肝病 1月21日，礼来GIP/GLP-1双受体激动剂替尔泊肽拟纳入突破性疗法，用于治疗代谢相关脂肪性肝病 RTX-117 白质消融性白质脑病 1月21日，ReviR溪砾科技RTX-117在华获批临床，用于治疗白质消融性白质脑病 GLP-1受体激动剂RO7795081 体重管理 1月20日，罗氏GLP-1受体激动剂RO7795081在华获批临床，拟用于超重或肥胖患者的长期体重管理 CD3/CD20双抗Epcoritamab 弥漫性大B细胞淋巴瘤 1月20日，艾伯维CD3/CD20双抗Epcoritamab临床三期失败，用于治疗复发/难治性弥漫性大B细胞淋巴瘤，失败理由是总生存期未显示有统计学意义的显著改善 FRα ADC Sofetabart mipitecan 腹膜癌 1月20日，礼来款FRα ADC Sofetabart mipitecan获FDA突破性疗法资格，用于治疗既往接受过贝伐珠单抗治疗、且符合用药条件的患者在接受过索米妥昔单抗治疗后的成人铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌 GPC3 RDC BAY3547926 肝细胞癌 1 月 20 日，拜耳GPC3 RDC BAY3547926 在国内获得临床试验默示许可，拟开发用于治疗肝细胞癌 LP(a)抑制剂HRS-5346 高脂蛋白 1月19日，恒瑞医药LP(a)抑制剂HRS-5346拟纳入突破性疗法，用于治疗脂蛋白（a）水平的升高图片来源于网络，版权归原作者侵删请联系药菓微信号｜iYaoGuo 点击关注，让我们的距离更近一步

免疫疗法细胞疗法优先审批上市批准抗体药物偶联物

2026-01-26

·药通社

年销35亿美元粉雾剂，新适应症获批！

1 月 23 日，GSK 宣布，国家药监局已批准全再乐®（氟替美维吸入粉雾剂，FF/UMEC/VI）新增适应症，用于成人哮喘患者的维持治疗。此次新适应症的获批，是对该产品原有慢性阻塞性肺疾病（COPD）适应症的扩展，也使氟替美维吸入粉雾剂成为中国目前首个且唯一可用于哮喘和 COPD 两种呼吸疾病维持治疗的单吸入装置的三联疗法（SITT）。此次获批主要基于 GSK 的 CAPTAIN 临床研究。该研究显示，对于吸入性糖皮质类固醇/长效 β2 受体激动剂（ICS/LABA）控制不佳的患者，与双联治疗 FF/VI 相比，使用 FF/UMEC/VI 提供的额外支气管扩张作用显著改善了肺功能。氟替美维吸入粉雾剂是一种每日一次、通过单次吸入给药的单吸入装置三联疗法。它包含三种成份：吸入性糖皮质激素（ICS）糠酸氟替卡松（FF）、长效抗胆碱能药物（LAMA）乌美溴铵（UMEC）、以及长效 β2 受体激动剂（LABA）三苯乙酸维兰特罗（VI），通过 GSK 独有的 Ellipta® 干粉吸入器给药。氟替美维吸入粉雾剂已在中美欧日等多个国家和地区上市，在国内批准的规格包括：100/62.5/25 μg（适用于哮喘及 COPD 适应症），以及 200/62.5/25 μg（适用于哮喘适应症）。自上市以来，该产品销售额一路突飞猛进，2024 年达到了 34.52 亿美元，2025 年前三季度为 29.42 亿美元。在国内，GSK于2019年上市，市场规模逐年递增，稳步上涨，目前销售额已达到五亿以上。图源：摩熵医药参考：药物递送 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

临床研究

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	R03AL08	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	加拿大	GlaxoSmithKline, Inc.	2018-05-30
慢性支气管炎	加拿大	GlaxoSmithKline, Inc.	2018-04-04
慢性阻塞性肺疾病	美国	GlaxoSmithKline Intellectual Property Development Ltd.	2017-09-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性哮喘	临床3期	美国	GSK Plc	2023-04-25
急性哮喘	临床3期	阿根廷	GSK Plc	2023-04-25
急性哮喘	临床3期	澳大利亚	GSK Plc	2023-04-25
急性哮喘	临床3期	智利	GSK Plc	2023-04-25
急性哮喘	临床3期	新西兰	GSK Plc	2023-04-25
急性哮喘	临床3期	韩国	GSK Plc	2023-04-25
心血管疾病	临床3期	美国	Glaxo Group Ltd.	2012-01-25
心血管疾病	临床3期	美国	葛兰素史克（中国）投资有限公司	2012-01-25
心血管疾病	临床3期	日本	葛兰素史克（中国）投资有限公司	2012-01-25
心血管疾病	临床3期	日本	Glaxo Group Ltd.	2012-01-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04937387 (CTgov)	临床3期	哮喘	359	Fluticasone Furoate [FF]+Vilanterol [VI] (Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug)	艱獵築憲鑰夢艱廠糧簾(襯壓築膚窪鏇艱蓋夢網) = 醖淵廠簾蓋鑰顧遞鹽顧蓋壓夢憲選製築觸窪觸 (範築膚網鬱衊廠願鏇獵, 0.0321) 更多	-	2025-08-11
				Fluticasone Furoate [FF]+Vilanterol [VI]+Umeclidinium [UMEC] (Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug)	艱獵築憲鑰夢艱廠糧簾(襯壓築膚窪鏇艱蓋夢網) = 壓夢鹹獵蓋廠膚鹹築獵蓋壓夢憲選製築觸窪觸 (範築膚網鬱衊廠願鏇獵, 0.0316) 更多
ATS2025	临床3期	慢性阻塞性肺疾病 St George's Respiratory Questionnaire (SGRQ)-C questions 1 (cough)	-	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	願壓膚顧鑰構繭範製衊(獵顧襯繭鑰鑰襯衊製網) = 顧鹽夢糧製網醖鏇艱廠積膚鬱顧簾醖艱艱膚衊 (築構壓淵糧窪積糧鏇製 )	积极	2025-05-16
				Budesonide/Formoterol (BUD/FOR)	願壓膚顧鑰構繭範製衊(獵顧襯繭鑰鑰襯衊製網) = 艱鬱窪範鬱醖製齋範網積膚鬱顧簾醖艱艱膚衊 (築構壓淵糧窪積糧鏇製 )
NCT04923347 (CTgov)	临床4期	慢性阻塞性肺疾病	229	fluticasone furoate+vilanterol+umeclidinium	選鏇餘鏇艱夢簾製範簾 = 憲築衊夢遞積願襯鹹膚鹹齋膚衊顧鬱艱積窪選 (膚鏇艱簾鑰築範醖積淵, 繭醖鹽壓願膚築積膚蓋 ~ 襯觸廠觸廠膚繭夢衊築) 更多	-	2025-03-24
NCT05535972 (CTgov)	临床4期	慢性阻塞性肺疾病	463	fluticasone furoate+vilanterol+Trelegy+umeclidinium	壓鹽夢蓋鑰鹹觸壓艱積(遞壓範膚壓簾獵夢餘淵) = 獵簾鬱鹹淵壓遞衊網鏇網淵簾獵鹹淵餘選鏇淵 (範糧餘願廠選簾鬱鹹網, 5.49) 更多	-	2024-11-04
ATS2024	N/A	慢性阻塞性肺疾病 \| 哮喘	-	FF/UMEC/VI-100	齋製淵糧顧壓餘觸鏇簾(蓋蓋艱鹽醖鬱顧夢鑰窪) = 製顧獵鏇憲壓醖壓鑰齋鑰構範夢夢糧淵糧鹹築 (鏇糧遞鏇鑰鏇鹽蓋醖廠 ) 更多	-	2024-05-19
				FF/UMEC/VI-200	齋製淵糧顧壓餘觸鏇簾(蓋蓋艱鹽醖鬱顧夢鑰窪) = 鏇蓋鑰淵淵齋醖淵簾觸鑰構範夢夢糧淵糧鹹築 (鏇糧遞鏇鑰鏇鹽蓋醖廠 ) 更多
NCT02924688 (CAPTAIN, ATS2024)	临床3期	哮喘维持	-	FF/UMEC/VI 100/62.5/25mcg	憲鏇鬱觸鑰艱艱窪鏇齋(鬱網鏇鏇鏇淵顧廠構鹹) = 獵選製選構獵鏇製衊網鹽鑰鑰範壓構膚網鹹構 (簾選選簾積襯鏇齋遞壓 )	-	2024-05-19
				FF/UMEC/VI 200/62.5/25mcg	憲鏇鬱觸鑰艱艱窪鏇齋(鬱網鏇鏇鏇淵顧廠構鹹) = 醖糧網繭獵遞選壓鏇繭鹽鑰鑰範壓構膚網鹹構 (簾選選簾積襯鏇齋遞壓 )
ATS2024	N/A	慢性阻塞性肺疾病	-	Prompt initiation of FF/UMEC/VI	鏇範選願簾簾齋窪鏇餘(遞艱鑰繭顧醖遞蓋憲範) = 廠衊餘鬱築繭餘顧構壓築選糧蓋窪齋積築衊憲 (蓋艱窪鬱壓鏇艱餘壓鹽 ) 更多	积极	2024-05-19
				Delayed initiation of FF/UMEC/VI	鏇範選願簾簾齋窪鏇餘(遞艱鑰繭顧醖遞蓋憲範) = 膚蓋選壓艱齋鏇遞襯廠築選糧蓋窪齋積築衊憲 (蓋艱窪鬱壓鏇艱餘壓鹽 ) 更多
ATS2024	N/A	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol	網繭憲鬱觸窪製構獵鹹(範窪積襯選鬱鏇齋鬱鏇) = 憲獵構蓋衊醖鏇選遞簾鬱鹽憲顧襯選憲鑰淵糧 (膚簾網壓積蓋鹽觸鹽齋 )	-	2024-05-19
				Budesonide/Formoterol	網繭憲鬱觸窪製構獵鹹(範窪積襯選鬱鏇齋鬱鏇) = 憲鹹構夢壓蓋製壓糧艱鬱鹽憲顧襯選憲鑰淵糧 (膚簾網壓積蓋鹽觸鹽齋 )
NCT04651777 (ETHA, CTgov)	临床3期	哮喘	31	FF/UMEC/VI	蓋遞選遞廠憲選夢願遞(窪觸範襯蓋齋遞淵憲鬱) = 膚窪鏇衊獵鑰窪膚觸構艱鏇鏇觸鹹遞憲範鹹醖 (糧襯簾積餘淵觸鬱鹽顧, 12) 更多	-	2024-03-29
AAAAI2024	N/A	哮喘	-	Fluticasone Furoate/Umeclidinium/Vilanterol-100	艱膚願蓋窪窪齋糧獵範(顧廠餘遞鑰壓鏇醖獵鑰) = 憲襯積衊糧淵襯鑰齋淵膚夢糧鹹顧簾衊觸積簾 (糧選廠蓋遞繭積鬱範簾 ) 更多	-	2024-02-23
				Fluticasone Furoate/Umeclidinium/Vilanterol-200	艱膚願蓋窪窪齋糧獵範(顧廠餘遞鑰壓鏇醖獵鑰) = 築網鏇鏇憲鏇襯顧鏇壓膚夢糧鹹顧簾衊觸積簾 (糧選廠蓋遞繭積鬱範簾 ) 更多